Last reviewed · How we verify
Beta blocker/digoxine/amiodarone
This is a combination therapy using three distinct cardiac drugs that work synergistically to reduce heart rate, increase cardiac contractility, and suppress arrhythmias.
This is a combination therapy using three distinct cardiac drugs that work synergistically to reduce heart rate, increase cardiac contractility, and suppress arrhythmias. Used for Atrial fibrillation with rapid ventricular response, Heart failure with reduced ejection fraction, Ventricular arrhythmias.
At a glance
| Generic name | Beta blocker/digoxine/amiodarone |
|---|---|
| Also known as | Negative chronotropic drugs pharmacological treatment . |
| Sponsor | Hospital Clinic of Barcelona |
| Drug class | Combination antiarrhythmic/inotropic therapy |
| Target | Beta-adrenergic receptors, Na+/K+-ATPase, cardiac ion channels (sodium, potassium, calcium) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Beta blockers reduce heart rate and contractility by blocking beta-adrenergic receptors. Digoxin increases cardiac contractility and slows AV node conduction through vagomimetic effects and Na+/K+-ATPase inhibition. Amiodarone is a broad-spectrum antiarrhythmic that blocks multiple ion channels (sodium, potassium, calcium) and has beta-blocking and calcium channel-blocking properties, making it effective for various arrhythmias.
Approved indications
- Atrial fibrillation with rapid ventricular response
- Heart failure with reduced ejection fraction
- Ventricular arrhythmias
- Supraventricular tachycardia
Common side effects
- Bradycardia
- Hypotension
- Fatigue
- Nausea
- Pulmonary toxicity (amiodarone)
- Thyroid dysfunction (amiodarone)
- Digoxin toxicity
- Photosensitivity (amiodarone)
Key clinical trials
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation (NA)
- Optimising Pacing Therapy, Integrated Medical Therapy, and Catheter AbLation for Atrial Fibrillation in Heart Failure Trial (PHASE4)
- Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial Fibrillation (NA)
- Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation (PHASE4)
- Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation (PHASE4)
- Danish Evaluation of Early Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure (NA)
- Lenient Rate Control Versus Strict Rate Control for Atrial Fibrillation. The Danish Atrial Fibrillation Randomised Clinical Trial (NA)
- Rapid Atrial Fibrillation Treatment Strategy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beta blocker/digoxine/amiodarone CI brief — competitive landscape report
- Beta blocker/digoxine/amiodarone updates RSS · CI watch RSS
- Hospital Clinic of Barcelona portfolio CI